Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Age greater than or equal to 18 years.~Kaposi's sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology.~Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.~Life expectancy greater than 6 months.~The following hematologic parameters:~* Hemoglobin greater than 9 g/dl;~* White blood cell (WBC) greater than 1000/mm\^3;~* Absolute neutrophil count (ANC) greater than 750/mm\^3;~* Platelets greater than 75,000/mm\^3;~* Prothrombin time (PT) and partial thromboplastin time (PTT) less than or equal to 120% of control, unless patient has the presence of a lupus anticoagulant.~The following hepatic parameters:~Bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) unless the patient is receiving protease inhibitor therapy known to be associated with increased bilirubin:~in this case total bilirubin less than or equal to 7.5 mg/dl and the direct fraction less than or equal to 0.7 mg/dl.~-Examples of protease inhibitors known to increase bilirubin levels include indinavir, ritonavir, nelfinavir, and atazanavir.~Aspartate aminotransferase (AST)/glutamic oxaloacetic transaminase (GOT) less than or equal to 2.5 times the upper limit of normal.~Either Serum creatinine less than or equal to 1.5 mg/dL or measured creatinine clearance greater than or equal to 60 mL/min.~Either Urine protein less than 1+ or measured 24 hour urine protein less than 500 milligram.~Blood pressure: systolic blood pressure (SBP) less than 160 mm/Hg; diastolic blood pressure (DBP) less than 95 mm/Hg.~At least 5 assessable cutaneous lesions previously untreated by local therapy.~Patients with human immunodeficiency virus (HIV) infection must be willing to comply with a regimen of highly active antiretroviral therapy and be on a regimen of highly active antiretroviral therapy (HAART) selected for best potential efficacy for at least 1 month with evidence of Kaposi sarcoma (KS) progression on the HAART regimen or be on a optimized regimen of HAART for 4 months or longer with no evidence of KS regression.~Patients must be willing to use effective birth control.~EXCLUSION CRITERIA:~Symptomatic, extensive pulmonary involvement.~Symptomatic visceral KS excluding the oral cavity.~Inability to provide informed consent.~Chemotherapy within 3 weeks.~Prior therapy with SU5416.~Supraphysiologic doses of corticosteroids within 3 weeks.~Major surgical procedure (including periodontal) within 4 weeks.~Surgical or other non-healing wounds unrelated to KS.~Pregnancy.~Breast feeding.~Past or present history of malignant tumors other than KS unless: a) in a complete remission for greater than or equal to 1 year from the time a response was first documented; b) completely resected basal cell carcinoma; or c) in situ squamous cell carcinoma of the cervix or anus.~Evidence of a severe or life-threatening infection within 2 weeks of entry onto the study.~A condition that would require the patient to receive intravenous antibiotics on a day of bevacizumab infusion.~Need for chronic daily aspirin greater than or equal to 325 mg/daily or nonsteroidal medication interfering with platelet function.~Therapeutic anticoagulation with international normalized ratio (INR) greater than 1.5, unless the patient is on full dose warfarin. If a patient is on full-dose anticoagulants, the following criteria should be met for enrollment:~The subject must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of low molecular weight (LMW) heparin;~The subject must not have active bleeding or pathological conditions that carry high risk of bleeding (e.g. tumor involving major vessels).~History of deep venous or arterial thrombosis.~History of gastrointestinal bleeding.~Clinically significant cardiovascular disease such as uncontrolled hypertension (with systolic BP greater than 160 mm/Hg or diastolic blood pressure greater than 95 mm/Hg), unstable angina, New York Heart Association grade II or greater congestive heart failure, cardiac arrhythmia requiring medication, clinically significant peripheral artery disease, grade II or greater peripheral vascular disease, myocardial infarction.~Substantial central nervous system (CNS) disease including history of CNS bleeding, mass lesions in the brain, uncontrolled seizure disorder, recent history of cerebrovascular accident (CVA) (e.g. within the past 6 months), history of transient ischemic attack (TIA) within the past 6 months..~Coagulopathy.~Patients with unstable bone fractures that are not stress/weight bearing able.~Patients with any other abnormality that would be scored as a grade 3 toxicity, except lymphopenia, direct manifestations of KS, direct manifestation of HIV, direct manifestation of HIV therapy, hyperbilirubinemia associated with protease inhibitors, asymptomatic hyperuricemia.~Previous intravenous immunoglobulin (IVIG) or monoclonal antibody therapy within 30 days prior to enrollment.~Known hypersensitivity to bevacizumab.~Known hypersensitivity to Chinese hamster ovary cell products.~Known hypersensitivity to other recombinant human or humanized antibodies.~Previous bevacizumab.~Any condition that, in the opinion of the Principal Investigator or Study Chairperson, would preclude the inclusion of a patient onto this research study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Pts with HIV-associated Kaposi's Sarcoma (Type: EXPERIMENTAL): 15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
- Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected) (Type: EXPERIMENTAL): 15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).